CRESTOVO
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota™ (FSM™) that harnesses the human gut microbiome. Crestovo is advancing the foundational clinical research of the company’s academic collaborators, Dr. Thomas Borody, Dr. Alexander Khoruts and Dr. Michael Sadowsky, which demonstrated in-human validation of an orally-available, microbiota-based product across a variety of serious diseases and unmet medical needs, including recurrent CDI. Crestovo’s lead Full-Spectrum Microbiota™ (FSM™) product, CP101, is currently being evaluated in the PRISM 3 clinical trial in patients with recurrent CDI.
CRESTOVO
Industry:
Biotechnology Pharmaceutical
Founded:
2014-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.crestovo.com
Status:
Active
Contact:
(800) 881-9361
Email Addresses:
[email protected]
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Cloudflare Hosting Cloudflare DNS Pound Sterling Japanese Yen Mimecast
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Official Site Inspections
http://www.crestovo.com
- Host name: 104.21.54.81
- IP address: 104.21.54.81
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Crestovo"
Crestovo Company Profile 2024: Valuation, Investors, Acquisition ...
Crestovo General Information Description. Developer of orally-administered microbiome designed to deliver novel therapeutics. The company's orally-administered microbiome develops full …See details»
Crestovo - Crunchbase Company Profile & Funding
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiotaâ„¢ (FSMâ„¢) that harnesses the human gut microbiome. Crestovo is advancing the foundational …See details»
Finch Therapeutics & Crestevo Merge to Form Fully Integrated …
Oct 25, 2017 The new entity, Finch Therapeutics Group, combines Crestovo’s extensive IP assets and late-stage candidate for recurrent C. difficile infections, CP101, an oral Full …See details»
Finch Therapeutics and Crestovo Announce Merger to Form Finch ...
Oct 23, 2017 Crestovo is advancing the foundational clinical research of the company’s academic collaborators, Dr. Thomas Borody, Dr. Alexander Khoruts and Dr. Michael …See details»
Crestovo Inc. Company Profile | Cambridge, MA - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Crestovo Inc. of Cambridge, MA. Get the latest business insights from Dun & Bradstreet.See details»
Crestovo - Products, Competitors, Financials, Employees, …
Originally licensed to CIPAC LLC who merged with Crestovo LLC in 2015, and Crestovo merged with Finch Therapeutics in 2017. *Vytacera Pharma Technology for the prevention and …See details»
Finch Therapeutics, Crestovo Merge to Create Microbiome Firm …
Oct 24, 2017 The new entity combines Crestovo's IP assets and late-stage candidate for recurrent C. difficile infections, CP101 with Finch's commercial-scale manufacturing …See details»
Crestovo LLC: Contact Details and Business Profile
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiotaâ„¢ (FSMâ„¢) that harnesses the human gut microbiome. Crestovo is advancing the foundational …See details»
Crestovo Inc - Company Profile and News - Bloomberg Markets
Company profile page for Crestovo Inc including stock price, company news, executives, board members, and contact informationSee details»
Takeda's Partner Merges With Crestovo to Form Finch ... - BioSpace
Takeda's Partner Merges With Crestovo to Form Finch ... - BioSpaceSee details»
Finch, Crestovo merger pushes forward C diff therapeutic
Oct 24, 2017 The deal will combine Crestovo's clinical stage microbiota product and Finch's commercial-scale manufacturing capabilities, discovery platform and product pipeline. Finch …See details»
Crestovo - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota that harnesses the human gut microbiome. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log In. Organization. Crestovo . Connect to CRM . Save . Summary.See details»
Microbiome merger flies Finch into phase 2 trial - Fierce Biotech
Oct 23, 2017 Lobacki was interim CEO of Crestovo before the merger. The COO is joined at Finch by Tom Borody, M.D. A Crestovo scientific founder, Borody will serve as an advisor to …See details»
Finch Therapeutics acquires Crestovo - 2017-10-23 - Crunchbase
Finch Therapeutics acquires Crestovo on 2017-10-23 for an undisclosed amount. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. ... Save . Summary. Overview. Edit Overview Section. Acquired Organization: Crestovo Crestovo is a clinical-stage biopharmaceutical company developing Full-Spectrum Microbiota that ...See details»
Finch Therapeutics Group Raises $36 Million in Series B Financing
Mar 1, 2018 Through a strategic merger with Crestovo in 2017, Finch established a leading position in addressing the C. difficile epidemic with Crestovo’s lead Full-Spectrum Microbiota product, CP101, which is currently being evaluated among patients suffering from recurrent C. difficile infections.See details»
BioCentury - Microbiome companies Finch and Crestovo merge
Oct 27, 2017 Microbiome companies Crestovo LLC (Cambridge, Mass.) and Finch Therapeutics Inc. (Somerville, Mass.) merged to form Finch Therapeutics Group (Somerville, Mass.), which …See details»
With $36M series B, Finch goes full speed ahead in microbiome …
Mar 1, 2018 Six months before Finch tied the knot with Crestovo, it inked a pact with Takeda that saw the Japanese pharma hand over $10 million for the worldwide rights to FIN-524, as well …See details»
Crestovo LLC Employer Profile - MassBio Career Center
Crestovo is a clinical-stage biopharmaceutical company focused on harnessing the power of the human gut microbiome to deliver innovative therapeutics. Through the highest quality scientific and clinical research, our vision is to become the premier microbiome company in restoring health and quality of life for patients.See details»
Crestovo Management Team - CB Insights
Explore {Crestovo's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Crestovo CEO, Founder, Key Executive Team, Board of Directors & EmployeesSee details»
Crestovo Doses Patients in PRISM 3, a Clinical Trial of CP101, a ...
Jun 27, 2017 CP101 is Crestovo’s potential first-in-class, lead microbiome therapy generated from the company’s Full-Spectrum Microbiota TM (FSM TM) platform. As an encapsulated, …See details»